Cargando…

Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry

INTRODUCTION: The PROOF registry is a prospective, observational study that aimed to monitor disease progression in a real-world cohort of patients with idiopathic pulmonary fibrosis (IPF). Here, longitudinal quality-of-life (QoL) outcomes, healthcare resource use (HCRU), and the association between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wuyts, Wim A., Dahlqvist, Caroline, Slabbynck, Hans, Schlesser, Marc, Gusbin, Natacha, Compere, Christophe, Maddens, Sofie, Rizzo, Shemra, Kirchgaessler, Klaus-Uwe, Bartley, Karen, Bondue, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098727/ https://www.ncbi.nlm.nih.gov/pubmed/35429319 http://dx.doi.org/10.1007/s41030-022-00187-8

Ejemplares similares

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A, et al.
Publicado: (2018)

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A., et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
por: Rinciog, C., et al.
Publicado: (2020)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Predominant dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: to be distinguished from idiopathic pulmonary fibrosis
por: Slabbynck, Hans, et al.
Publicado: (2017)

The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis
por: Moor, C. C., et al.
Publicado: (2020)

The 6-min walk test as a primary end-point in interstitial lung disease
por: Harari, Sergio, et al.
Publicado: (2022)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Mohs surgery: proclamation, proof, principles, and promise
por: Bartley, George B
Publicado: (2004)

Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2019)

Electronically monitored medication adherence in idiopathic pulmonary fibrosis: prevalence, predictors and outcomes
por: Delameillieure, Anouk, et al.
Publicado: (2022)

Idiopathic pleuroparenchymatous fibroelastosis: A case report and brief review of the literature
por: Cuppens, Kristof, et al.
Publicado: (2014)

Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey
por: Lancaster, Lisa H., et al.
Publicado: (2020)

Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models
por: Wuyts, Wim A., et al.
Publicado: (2014)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

281. Prevalence of Influenza Co-infection in a Real-world Cohort of COVID-19 Patients in the U.S
por: Chawla, Devika, et al.
Publicado: (2021)

26. Risk of Post–COVID-19 Dyspnea and Interstitial Lung Disease (ILD) in a Real-World Cohort of Patients Hospitalized with COVID-19 in the United States
por: Zalocusky, Kelly, et al.
Publicado: (2021)

Patients’ and healthcare professionals’ perspectives on the idiopathic pulmonary fibrosis care journey: a qualitative study
por: Delameillieure, Anouk, et al.
Publicado: (2021)

Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?
por: Wuyts, Wim A., et al.
Publicado: (2014)

Care programs and their components for patients with idiopathic pulmonary fibrosis: a systematic review
por: Delameillieure, Anouk, et al.
Publicado: (2021)

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)
por: Gotfried, Mark H., et al.
Publicado: (2018)

Behavioural and psychological patterns of patients with idiopathic pulmonary fibrosis: a prospective study
por: Delameillieure, Anouk, et al.
Publicado: (2022)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

515. Evolution of Treatment Patterns for Patients Hospitalized with COVID-19 in the United States
por: Zalocusky, Kelly, et al.
Publicado: (2021)

322. Risk Factors for COVID-19 Disease Severity Using Electronic-Health Records in a Real-World Cohort in the United States
por: Rizzo, Shemra, et al.
Publicado: (2021)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Factors associated with COVID-19 viral and antibody test positivity and assessment of test concordance: a retrospective cohort study using electronic health records from the USA
por: Lindsay, Lisa, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management
por: van Cleemput, Johan, et al.
Publicado: (2018)

Patient Registries in Idiopathic Pulmonary Fibrosis
por: Culver, Daniel A., et al.
Publicado: (2019)

Utility of Stapedial Reflex in Idiopathic Intracranial Hypertension: The Proof is in the Pudding
por: Prakash, Sanjay, et al.
Publicado: (2022)

Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis
por: Stijn, Willems, et al.
Publicado: (2013)

Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
por: Wijsenbeek, Marlies S., et al.
Publicado: (2022)

Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis
por: Guiot, J., et al.
Publicado: (2016)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
por: McDonough, John E, et al.
Publicado: (2019)

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
por: Wuyts, Wim A., et al.
Publicado: (2016)

Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
por: Delanote, Isabelle, et al.
Publicado: (2016)

Twin Registries: The Neglected Population Resource
por: Elwadhi, Deeksha, et al.
Publicado: (2017)

Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
por: de Andrade, Joao A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pfjdsb72pq2aheqvnrp3v6qk4c